anyone else notice dose escalation kicking in around week 37
anyone else notice dose escalation kicking in around week 37. Posting the boring middle of the process, because the internet is full of the start and the end and nothing else.
Kept a log specifically because there is so little published. It is one person and it is not data.
Read the phase 2 paper twice before ordering anything. Recommend that to anyone in this board: the error bars are the interesting part.
If two or three other people have done the same thing we might actually learn something. Alone it is an anecdote.
best — the order this archive was captured in
It is a triple agonist at the GLP-1, GIP and glucagon receptors. The glucagon arm is the genuinely novel component and it is the one with the least human outcome data behind it.
It is a triple agonist at the GLP-1, GIP and glucagon receptors.
Disagree with this specific inference. A 48-week readout does not tell you the shape of the curve after it.
wait for phase 3 before you argue about rankings
[removed by moderator]
Is that the 48-week figure or an earlier readout?
Right, and it bears repeating that nothing here is approved anywhere and research material is not for human use.
Increases in heart rate have been reported across this receptor class. The magnitude and clinical significance are exactly what phase 3 is powered to establish.
Disagree. "More receptors means more effect" is not how any of this works and the trial data does not support the linear story.
Same read. The energy-expenditure mechanism is the interesting bit and it is not established in humans at scale.
Phase 2 estimates effect and finds a dose range. Phase 3 estimates it precisely in a bigger population and catches what phase 2 was too small to see. Treating them as the same tier of evidence is the recurring error here.
the phase 2 numbers were striking and they were also 48 weeks in a small population
heart rate is the thing people report watching
the glucagon component is why the metabolic story reads differently
Agreed, and the framing that helps is: this is a phase 2 compound with phase 3 running. Everything else is inference.
What do you think the glucagon component is adding, specifically?
Watched heart rate on a wearable across twelve weeks because the threads said to. It moved a little and I have no idea whether that means anything.
Stopped at a low step because there was no reason to go further and no data to tell me what further would do.
Has anyone posted an independent test on this compound recently?
comparing reta phase 2 to sema phase 3 is comparing different things
What is the source for that figure — the published paper or a summary of it?
What is the source for that figure — the published paper or a summary of it?
This is the sentence the rest of the board should read first. Phase 2 is not a label.
The thing that surprised me was how much of the discussion here is inference rather than measurement.
- 1It is a triple agonist at the GLP-1, GIP and glucagon receptors. The…9 comments in this branch · started by u/yara_lindholm